Ertumaxomab: Difference between revisions
m (Protected "Ertumaxomab": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite))) |
m (Bot: Automated text replacement (-{{SIB}} + & -{{EJ}} + & -{{EH}} + & -{{Editor Join}} + & -{{Editor Help}} +)) |
||
Line 26: | Line 26: | ||
}} | }} | ||
{{SI}} | {{SI}} | ||
==Overview== | ==Overview== | ||
Line 33: | Line 33: | ||
{{rat-murinehybridmonoclonals}} | {{rat-murinehybridmonoclonals}} | ||
[[Category:Monoclonal antibodies]] | [[Category:Monoclonal antibodies]] | ||
[[Category:Cancer treatments]] | [[Category:Cancer treatments]] | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} |
Latest revision as of 02:22, 9 August 2012
WikiDoc Resources for Ertumaxomab |
Articles |
---|
Most recent articles on Ertumaxomab Most cited articles on Ertumaxomab |
Media |
Powerpoint slides on Ertumaxomab |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Ertumaxomab at Clinical Trials.gov Clinical Trials on Ertumaxomab at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Ertumaxomab
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Ertumaxomab Discussion groups on Ertumaxomab Patient Handouts on Ertumaxomab Directions to Hospitals Treating Ertumaxomab Risk calculators and risk factors for Ertumaxomab
|
Healthcare Provider Resources |
Causes & Risk Factors for Ertumaxomab |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Overview
Ertumaxomab (marketed under the brand name Rexomun®) is a rat-murine hybrid monoclonal antibody which it's used to treat some cancers.
Template:Rat-murinehybridmonoclonals
Template:WH
Template:WS